There is enormous enthusiasm in the scientific community for finding a cure for HIV. Although much remains to be discovered regarding the mechanisms of viral persistence and how it may be disrupted, some assumptions regarding the goals of a cure, applicability to target populations, and what is required of the assays we employ, may lead to missed opportunities and discoveries and hamper the discovery of a product that will safely cure tens of millions of HIV-infected people around the world. The field will benefit from an awareness and critical interrogation of assumptions that may be implicit in their scientific pursuits.
Get full access to this article
View all access options for this article.
References
1.
HutterG, NowakD, MossnerM, et al.: Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med, 2009; 360:692–698.
2.
CrowellTA, GeboKA, BlanksonJN, et al.: Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J Infect Dis, 2015; 211:1692–1702.
3.
DeeksSG, LewinSR, HavlirDV: The end of AIDS: HIV infection as a chronic disease. Lancet, 2013; 382:1525–1533.
4.
DeeksSG, TracyR, DouekDC: Systemic effects of inflammation on health during chronic HIV infection. Immunity, 2013; 39:633–645.
5.
PereyraF, PalmerS, MiuraT, et al.: Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis, 2009; 200:984–990.
6.
HsuePY, HuntPW, SchnellA, et al.: Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS, 2009; 23:1059–1067.
7.
HuntPW, BrenchleyJ, SinclairE, et al.: Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis, 2008; 197:126–133.
8.
PereyraF, LoJ, TriantVA, et al.: Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS, 2012; 26:2409–2412.
9.
KrishnanS, WilsonEM, SheikhV, et al.: Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis, 2014; 209:931–939.
10.
CockerhamLR, HatanoH: Elite control of HIV: Is this the right model for a functional cure?. Trends Microbiol, 2015; 23:71–75.
11.
KarrisMY, HaubrichRH: Antiretroviral therapy in the elite controller: Justified or premature?. J Infect Dis, 2015; 211:1689–1691.
12.
DaveyRTJr., BhatN, YoderC, et al.: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A, 1999; 96:15109–15114.
13.
HenrichTJ, HanhauserE, MartyFM, et al.: Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: Report of 2 cases. Ann Intern Med, 2014; 161:319–327.
14.
LuzuriagaK, GayH, ZiemniakC, et al.: Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med, 2015; 372:786–788.
15.
HillAL, RosenbloomDIS, KuritzkesDR, SilicianoRF, HenrichTJ: Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV. J Virus Erad, 2015; 1:13.
16.
VerdultF: CURE: The point of view of people living with HIV. Paper Presented at: Towards an HIV Cure, International AIDS Society, July 20–21, 2012, Amsterdam, The Netherlands.
17.
PeabodyR: Many people living with HIV willing to take part in cure research, despite its risks. Available at www.aidsmap.com/Many-people-living-with-HIV-willing-to-take-part-in-cure-research-despite-its-risks/page/2964488/, accessed April24, 2015.
18.
HurstJ, HoffmannM, PaceM, et al.: Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun, 2015; 6:8495.
19.
PapasavvasE, FoulkesA, YinX, et al.: Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients. Immunology, 2015; 145:380–390.
20.
YerlyS, GunthardHF, FagardC, et al.: Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS, 2004; 18:1951–1953.
21.
WilliamsJP, HurstJ, StohrW, et al.: HIV-1 DNA predicts disease progression and post-treatment virological control. Elife, 2014; 3:e03821.
22.
PikettyC, WeissL, AssoumouL, et al.: A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol, 2010; 82:1819–1828.
23.
ChurchillMJ, DeeksSG, MargolisDM, SilicianoRF, SwanstromR: HIV reservoirs: What, where and how to target them. Nat Rev Microbiol, 2016; 14:55–60.
24.
HoYC, ShanL, HosmaneNN, et al.: Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell, 2013; 155:540–551.
25.
ErikssonS, GrafEH, DahlV, et al.: Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog, 2013; 9:e1003174.
26.
ProcopioFA, FromentinR, KulpaDA, et al.: A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. EBioMedicine, 2015; 2:872–881.
27.
PersaudD, GayH, ZiemniakC, et al.: Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med, 2013; 369:1828–1835.
28.
Saez-CirionA, BacchusC, HocquelouxL, et al.: Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog, 2013; 9:e1003211.
29.
FrangeP, FayeA, Avettand-FenoëlV, BellatonE, DescampsD, AnginM, Caillat-ZucmanS, PeytavinG, Le Chenadec WarszawskiJ, RouziouxC, Saez-CirionA; on behalf of the French ANRS EPF-CO10 Pediatric Cohort: HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally-infected child. Paper Presented at: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2015, Vancouver Canada. Available at www.pasteur.fr/en/institut-pasteur/press/press-documents/first-case-prolonged-remission-12-years-hiv-infected-child#sthash.2dbptH9r.dpuf, accessed January11, 2016.
30.
HillAL, RosenbloomDI, FuF, NowakMA, SilicianoRF: Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A, 2014; 111:13475–13480.
31.
ConwayJM, PerelsonAS: Post-treatment control of HIV infection. Proc Natl Acad Sci U S A, 2015; 112:5467–5472.
32.
HillAL, HuL, HoganLE, NowakMA, HenrichTJ: Predicting determinants of long-term HIV control with gene therapy strategies. J Virus Erad, 2015; 1:41.
33.
PinkevychM, CromerD, TolstrupM, et al.: HIV reactivation from latency after treatment interruption occurs on average every 5–8 days—implications for HIV remission. PLoS Pathog, 2015; 11:e1005000.
34.
Adolescents PoAGfAa: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Services DoHaH, 2012. http://aidsinfo.nih.gov/guidelines, accessed January11, 2016.
35.
SafrenSA, MayerKH, OuSS, et al.: Adherence to Early antiretroviral therapy: Results from HPTN 052, a phase III, multinational randomized trial of ART to prevent HIV-1 sexual transmission in serodiscordant couples. J Acquir Immune Defic Syndr, 2015; 69:234–240.
36.
KentSJ, ReeceJC, PetravicJ, et al.: The search for an HIV cure: Tackling latent infection. Lancet Infect Dis, 2013; 13614–621.
37.
TebasP, SteinD, TangWW, et al.: Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med, 2014; 370:901–910.
38.
KarnJ: Estrogen blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirs. Paper Presented at: IAS 2015 Towards an HIV Cure Symposium, 2015, Vancouver, Canada.
39.
De VoeghtA, MaesN, MoutschenM: sCD14 is not a bona-fide biomarker of microbial translocation in HIV-1 infected Africans living in Belgium. AIDS, 2015 [Epub ahead of print]; DOI: 10.1097/QAD.0000000000000996.
40.
JohnstonRE, HeitzegMM: Sex, age, race and intervention type in clinical studies of HIV cure: A systematic review. AIDS Res Hum Retroviruses, 2015; 31:85–97.
41.
AltfeldM, RosenbergES, ShankarappaR, et al.: Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med, 2001; 193:169–180.
42.
JainV, HartogensisW, BacchettiP, et al.: Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis, 2013; 208:1202–1211.
43.
HoggR, CahnP, KatabiraET, et al.: Time to act: Global apathy towards HIV/AIDS is a crime against humanity. Lancet, 2002; 360:1710–1711.
44.
RabkinM, El-SadrW, KatzensteinDA, et al.: Antiretroviral treatment in resource-poor settings: Clinical research priorities. Lancet, 2002; 360:1503–1505.
45.
WHO: Guideline on When to Start Antiretroviral Therapy and on Pre-exposure Prophylaxis for HIV. WHO, Geneva, 2015.
